Biotech Daily

Tuesday August 4, 2026

Daily news on ASX-listed biotechnology companies

*** ASX, BIOTECH UP: SALUDA UP 35%; IMPEDIMED DOWN 20%**

*** CONTROL BIONICS WINS FDA NEUROSTRIP DEVICE REGISTRATION**

*** AMPLIA, ELI LILLY AMP945, OLOMORASIB LUNG CANCER TRIAL**

*** NEUROTECH $4.5m PLACEMENT**

*** LUMOS $1.1m PHASE SCIENTIFIC FEBRIDX ORDER**

*** AUDEARA $31k A.I. AUDIO PROCESSOR ORDERS**

*** FLINDERS UNI: DNA SEQUENCING CYSTIC FIBROSIS INFECTION TEST**

*** SNOW CENTRE INFECTION, DISEASE RESPONSE TWIN STUDY**

*** ARAVAX: 'FDA PVX108 PEANUT ALLERGY FAST TRACK STATUS'**

*** ENTROPY 72-PATIENT, 8-INDICATION TRP-8803 TRIAL APPROVAL**

*** NOXOPHARM 'SOFRA UNBLINDS IMMUNE CELLS TO CANCER, IN-VITRO'**

*** NOVA TAYLOR REPLACES HERAMED CO-CO SEC STEPHANIE VIPOND**

MARKET REPORT

The Australian stock market was up 1.4 percent on Tuesday August 4, 2026, with the ASX200 up 126.5 points to 9,145.8 points. Twenty-nine of the Biotech Daily Top 40 companies were up, six fell and five traded unchanged. All four Big Caps were up.

Saluda was the best, up 15 cents or 34.9 percent to 58 cents, with 1.5 million shares traded. Lumos climbed 23.8 percent; Amplia was up 14.8 percent; Dimerix rose 11.5 percent; Optiscan was up 10.3 percent; 4D Medical, Paradigm and Prescient were up more than eight percent; Actinogen and Medical Developments rose seven percent or more; Clarity, Micro-X and Nanosonics climbed six percent or more; Alcidion, EBR and Syntara were up more than five percent; Pro Medicus was up 4.9 percent; CSL, Imricor, Nova Eye, Orthocell and Proteomics were up more than three percent; Avita, Immutep and Mesoblast rose more than two percent; Artrya, Cochlear and Resmed were up more than one percent; with Cyclopharm, Neuren, Racura, Starpharma and Telix up by less than one percent.

Impedimed led the falls, down 0.1 cents or 20 percent to 0.4 cents, with 596,726 shares traded. Resonance fell 4.8 percent; Clarity and Emvision lost one percent or more; with Aroa and Polynovo down by less than one percent.

CONTROL BIONICS

Control Bionics says the US Food and Drug Administration has registered and listed its Neurostrip surface EMG (electro-myo-graphy) wearable platform as a medical device.
Control Bionics said the FDA registration and listing formalized Neurostrip's "recognized status in the US medical device market".
The company said the registration was not required for commercialization of Neurostrip "in sports performance and everyday rehabilitation", but was required for more advanced applications including clinical rehabilitation, medical research, human-computer interface and medical technologies development.
Control Bionics said the registration was "an important step in accelerating its growth strategy across all three Neurostrip application areas, performance, rehabilitation, and research and data, and as a further building block in Control Bionics' 25-year plus legacy as an innovative medtech business".
In 2024, the company said that its Neuronode had received a US Centers for Medicare and Medicaid (CMS) code qualifying it for $US4,300 ($A6,432) in reimbursement, from October 1, 2024 (BD: Aug 19, 2024).
Today, Control Bionics said it had pending regulatory applications for Australian Therapeutic Goods Administration registration, Conformite Europeenne mark and UK Medical Device Regulations registration.
Control Bionics managing-director Jeremy Steele said the FDA registration was "an important milestone for Control Bionics and for Neurostrip".
"It is a significant credential in its own right, and while Neurostrip already supports sports performance and everyday rehabilitation use without requiring this level of regulatory status, formal recognition under the US medical device framework meaningfully strengthens our position in advanced clinical rehabilitation, medical research and future human-computer interface applications, where customers and partners expect a recognized regulatory foundation," Mr Steele said.
Control Bionics fell 0.1 cents or 1.5 percent to 6.4 cents.

AMPLIA THERAPEUTICS

Amplia says with Eli Lilly it will conduct a phase Ib/IIb study of narmafotinib, AMP945, with Eli Lilly's KRAS G12C inhibitor olomorasib for non-small cell lung cancer.
Amplia managing-director Dr Chris Burns told Biotech Daily that Eli Lilly would supply olomorasib and Amplia would fund and conduct the Australian and US study.
Amplia said it worked with Eli Lilly on a "draft clinical study protocol and will now collaborate to finalize both the protocol and other associated clinical study documents".
Earlier this year, Amplia said mouse data showed its focal adhesion kinase (FAK) inhibitor narmafotinib enhanced the activity of Kirsten rat sarcoma virus (KRAS) inhibitors in models of pancreatic cancer (BD: Mar 9, 2026).
At the time, the company said narmafotinib blocked resistance pathways that could emerge with KRAS-inhibitor treatment, "thereby enhancing efficacy and durability".
Today, Amplia said the study with Eli Lilly supported and enhanced its "strategy to position narmafotinib as a versatile oncology combination agent with the potential to enhance existing and investigational therapies across several high-value indications".
Dr Burns said the collaboration was "an exciting new stage" for narmafotinib.
"The combination of FAK and KRAS inhibition can lead to improved outcomes … with olomorasib, Lilly's leading KRAS G12C inhibitor currently undergoing two global phase III studies in [non-small cell lunger cancer]," Dr Burns said.
Amplia was up two cents or 14.8 percent to 15.5 cents with 21 million shares traded.

NEUROTECH INTERNATIONAL

Neurotech says it has “binding commitments” to raise about $4.5 million at 1.4 cents a share in a placement to “institutional and sophisticated investors”.
Biotech Daily calculates the price is a 12.5 percent discount to the 1.6 cents closing price.
Neurotech said the funds would be used for its phase III, double-blind, placebo-controlled trial of NTI164 for children with autism spectrum disorder as well as regulatory activities and general working capital.
The company said Taylor Collison and Canary Capital were joint lead managers.
Neurotech was up 0.1 cents or 6.25 percent to 1.7 cents with 2.9 million shares traded.

LUMOS DIAGNOSTICS HOLDINGS

Lumos says it has a $US767,800 ($A1,094,335) Febridx order from Phase Scientific, with delivery to be fulfilled by October 2026 and revenue recognized on shipment.
Last year, Lumos said it had an up-to $US317 million, six-year distribution and supply deal with Hong Kong’s Phase Scientific International Ltd for its Febridx test to differentiate bacterial from viral respiratory infections (BD: Jul 16, 2025).
In March, the company said the US Food and Drug Administration had granted Febridx a Clinical Laboratory Improvement Amendments (CLIA) waiver (BD: Mar 27, 2026).
Today, Lumos said the purchase order was “the initial order associated with the $US5.0 million pre-payment milestone received … following the grant of CLIA waiver”.
The company said the order satisfied part of the one-year minimum order commitment under the agreement with Phase and would be credited against the pre-payment, with the remaining pre-payment balance available to support subsequent purchase orders.
Lumos managing-director Doug Ward said the company was “encouraged by the continued momentum as we advance the commercialization of Febridx”.
“This order comes at an important time as US healthcare providers prepare for the upcoming flu season,” Mr Ward said.
“We look forward to supporting the continued adoption of rapid, point-of-care acute respiratory infection testing across the US market,” Mr Ward said.
Lumos was up 2.5 cents or 23.8 percent to 13 cents with 6.3 million shares traded.

AUDEARA

Audeara says it has $31,000 in orders following production in two product programs under its artificial intelligence (A.I.) audio processing algorithm licence with Optek.
Last year, Audeara said it would licence its A.I. audio processing algorithms for use in the Shenzhen, China-based Optek Microelectronics’ products (BD: Dec 16, 2025).
Today, the company said it had first commercial production purchase orders for the licenced technology in both customer product programs, following a period of development with Optek.
Audeara said it received revenue on a fee-per-chip basis for each approved production unit using its technology, with future revenue to be recognized as additional licenced products were ordered and manufactured under approved customer programs.
Audeara managing-director Dr James Fielding said the orders were “an important milestone for Audeara as we have demonstrated that our A.I. audio technology can be successfully deployed ‘on chip’ which makes us a valuable provider moving forwards”.
“This first deployment validates both our capital light licencing strategy and proves a pathway for our technology to be deployed efficiently and at scale,” Dr Fielding said.
Audeara was unchanged at 3.1 cents.

FLINDERS UNIVERSITY

Flinders University says its DNA sequencing can provide more accurate identification of microbial infections to address risks from long-term antibiotic use in cystic fibrosis.

Flinders University said that the research followed the introduction of cystic fibrosis trans-membrane conductance regulator (CFTR) modulator therapies, which were designed to correct the malfunctioning protein that causes the disease.

The University said cystic fibrosis patients developed “an abnormal amount of excessively thick and sticky mucus within the lungs, airways and the digestive system”, which caused impairment of the digestive functions of the pancreas and trapped bacteria in the lungs resulting in recurrent infections, leading to irreversible damage.

Flinders University said DNA sequencing was transforming the diagnosis and management of infections, “revealing entire microbial communities instead of single pathogens and paving the way for faster, more precise, and personalized treatment”.

The University said that a summary of the article, titled ‘DNA sequencing for microbial surveillance in cystic fibrosis airways: Advances, challenges, and clinical translation’ was published in Clinical Microbiology Reviews and was available at: https://journals.asm.org/doi/10.1128/cmr.00352-25.

Flinders University said that its researchers were “also exploring the use of portable sequencing devices, some no larger than a mobile phone and capable of connecting directly to a laptop, to make rapid DNA sequencing accessible in hospitals, and even remote and rural settings”.

The University said that the methods could be used to reveal both “the composition and diversity of the airway microbiome as well as strain-level variation, anti-microbial resistance (AMR) genes, virulence determinants and microbial metabolic functions”.

Flinders University said it would “take further testing for sequencing to become part of routine clinical practice in Australia, but it has great promise in transforming the diagnosis and management of infectious diseases as well as cystic fibrosis”.

Flinders University research associate Dr Jessica Carlson-Jones said DNA sequencing was “a powerful tool which can monitor these microbial changes, detect infections more rapidly than traditional laboratory methods and identify antimicrobial resistance”.

“Beyond cystic fibrosis, the same technology is being applied to other infectious diseases, where rapid identification of pathogens can lead to earlier diagnosis, more targeted treatments and improved patient outcomes,” Dr Carlson-Jones said.

SNOW CENTRE FOR IMMUNE HEALTH

The Snow Centre for Immune Health says it will conduct a 200-patient study of twins to evaluate why people respond differently to infections, diseases and treatments.

The Snow Centre said the study with the University of Melbourne’s Twins Research Australia would enrol 100 pairs of identical and non-identical twins aged 18-to-80 years old and use its Cyton2 cell timer model technology to “track how immune cells act over time”, examining how immune function varies by age, sex, and genetic inheritance.

The Centre said that by comparing twins who responded differently to the same immune challenges, researchers could “estimate how much of the differences are genetic and how much are environmental”.

The Snow Centre said the findings would “support advances in personalized medicine and more targeted treatments for immune-related conditions, such as type 1 diabetes, rheumatoid arthritis, multiple sclerosis, and others”.

The Centre said further information was available at: www.twins.org.au.

ARAVAX PTY LTD

Melbourne's Aravax says it has US Food and Drug Administration fast track designation for its lead product PVX108 for the treatment of peanut allergy.

In 2019, Aravax said its 48-patient, phase I, PVX108 trial showed "a highly favorable safety profile, even in patients with severe peanut allergies" (BD: Feb 26, 2019).

In 2024, the company said it enrolled all 95 patients, aged four-to-17 years old, in its double-blind, placebo-controlled phase II study of PVX108 as a treatment for peanut allergies (BD: Oct 28, 2024).

Today, Aravax said that the FDA fast track program enabled "the expedited development and review of new drugs or biologics that are intended to treat serious or life-threatening conditions and demonstrate the potential to address unmet medical needs".

The company said the designation provided eligibility for more frequent FDA meetings, more frequent written communication with the FDA, eligibility for accelerated approval and priority review and rolling review.

Aravax chief executive officer Dr Pascal Hickey said there remained "a critical need for effective new treatments for food allergy and we believe PVX108 has the potential to offer a safer, more convenient and disease modifying treatment for the millions affected by peanut allergy worldwide".

"Receiving FDA fast track designation is a significant step for PVX108's future development as being able to communicate more frequently with the FDA often leads to early drug approval and access by patients," Dr Hickey said.

Aravax is a private company.

ENTROPY NEURODYNAMICS (TRYPTAMINE THERAPEUTICS)

Entropy says it has ethics committee approval to begin a 72-patient, phase Ib/IIa study of its TRP-8803 intra-venous psilocin in eight indications.

Entropy said the study would assess intra-venous infused TRP-8803 psilocin in anorexia nervosa, body dysmorphic disorder, obsessive compulsive disorder, generalized anxiety disorder, post-traumatic stress disorder, treatment-resistant depression, fibromyalgia and irritable bowel syndrome.

The company said it had a clinical trial agreement with Melbourne's Swinburne University to conduct the "world-first initiative".

Last month, Entropy said the six-patient, first cohort of its phase I trial showed that TRP-8803 psilocin led to a 100 percent clinically meaningful improvement for binge eating disorder (BD: Jul 7, 2026).

Previously, the company said that psilocin was the active psychedelic metabolite of psilocybin found in 'magic mushrooms' (BD: Jul 1, 2024).

Today, Entropy said patients would receive two doses of TRP-8803 administered about two weeks apart alongside psychedelic-assisted psycho-therapy.

The company said the primary endpoint was safety, with secondary and exploratory endpoints assessing changes in anxiety, quality-of-life, disease-specific symptoms and patient-reported outcomes.

Entropy said the 'basket study' was designed to assess TRP-8803 in multiple indications within one clinical framework and would help "prioritize future development opportunities while strengthening the clinical evidence base".

The company said patients were expected to be recruited "shortly", with first patient dosing by October, subject to recruitment and operational timelines, and dosing completion by the end of 2026.

Entropy was up 0.1 cents or 2.9 percent to 3.6 cents with 9.3 million shares traded.

NOXOPHARM

Noxopharm says in-vitro data shows its Sofra-based oligo-nucleotides have “the potential to unblind immune cells to cancer RNA and unleash immune activation”.

Earlier this year, the Hudson Institute said with Noxopharm it had found “very short RNA fragments” which could be used to develop treatments for auto-inflammatory diseases and the development of Noxopharm’s SOF-SKN therapy (BD: Feb 11, 2026).

Today, Noxopharm said the study was conducted with the Hudson Institute and showed its oligo-nucleotides, which were short synthetic RNA sequences, “helped the immune system recognize and respond to cellular RNA that would normally go unnoticed”.

The company said the findings “could pave the way for a new type of cancer treatment that works alongside existing therapies, such as chemotherapy and radio-therapy, to help the immune system better initiate its anti-cancer response”.

Noxopharm was unchanged at 7.9 cents.

HERAMED

Heramed says Bio101 Financial Advisory’s Nova Taylor has been appointed joint company secretary with Cameron Jones, following Stephanie Vipond stepping down.

Heramed fell 0.1 cents or 2.9 percent to 3.4 cents.